发布时间：2025-04-29 股票投资评级 买入 |维持 证券研究报告：美容护理 | 公司点评报告 个股表现 2024-04 2024-07 2024-09 2024-11 2025-02 2025-04 -26% -22% -18% -14% -10% -6% -2% 2% 6% 10% 14% 18% 福瑞达 美容护理 资料来源：聚源，中邮证券研究所 公司基本情况 | 最新收盘价（元） | 7.55 | | --- | --- | | 总股本/流通股本（亿股）10.17 | / 10.17 | | 总市值/流通市值（亿元）77 | / 77 | | 52 周内最高/最低价 | 8.91 / 5.89 | | 资产负债率(%) | 20.2% | | 市盈率 | 31.46 | | 第一大股东 | 山东省商业集团有限公 | | 司 | | 研究所 分析师:李媛媛 SAC 登记编号:S1340523020001 Email:liyuanyuan@cnpsec.com 福瑞达(600223) 颐莲保持高增，静待瑷尔博士拐点 l 事件回顾 公司公布 25Q1 季报，25Q1 实现收入 8.8 亿元，同比-1.6 ...

事件 公司发布2024 年年报与2025 年1 季报：2024 年营收107.78 亿元 （同比+21.0%），归母净利润15.52 亿 元（同比+30.0%），扣非归母净利润15.22亿元（同比+29.6%）；2025Q1 营收23.59 亿元 （同比 +8.1%），归母净利润3.9 亿元（同比+28.9%），扣非归母净利润3.79 亿元（同比+29.8%）。 2024 年营收过百亿大关，利润增长不改龙头底色2024Q4 与2025Q1 均在收入稳健基础上实现20%+利润 增长，表观上受益于综合毛利率提升与费用端降本增效。我们认为，2024H2 电商平台流量竞争激烈， 美妆品牌利润率多承压，珀莱雅利润率逆势提升，背后是公司四大单品矩阵系列支撑（客单价与复购率 提升）、精细化运营与成本管控能力强、2020 年转型以来不断积蓄的品牌势能。 "大单品策略"持续夯实，看好美白/油皮等品类增量2024 年以来公司持续夯实"大单品策略"，包括升级 双抗系列、红宝石系列、源力系列核心大单品，丰富能量系列新品，全新推出盾护防晒、超膜银管防 晒、针对美白的光学系列、针对油皮的净源系列。存量大单品系列升级延长生命周期、美白/油 ...

Investment Rating - The report maintains a "Buy" rating for the company [5][3] Core Insights - The company achieved a revenue of 10.778 billion yuan in 2024, representing a year-on-year growth of 21.04%, with a net profit of 1.552 billion yuan, up 30.00% [1][3] - The company continues to experience robust growth, driven by its main brand and sub-brands, with a significant increase in online sales [2][12] - The company is focusing on a big product strategy and expanding its sub-brand matrix, indicating strong long-term growth potential [3][15] Financial Performance Summary - In 2024, the company reported a total revenue of 10.778 billion yuan, with a year-on-year growth of 21.04% [4][11] - The net profit attributable to the parent company for 2024 was 1.552 billion yuan, reflecting a growth of 30.00% [4][11] - The company’s gross margin improved to 71.39% in 2024, an increase of 1.46 percentage points from the previous year [14] - The company’s operating cash flow for 2024 was 1.107 billion yuan, a decrease of 24.63% year-on-year due to increased payments for goods and promotional expenses [14] Revenue Breakdown - Online sales accounted for 95.06% of total revenue in 2024, with online revenue reaching 10.234 billion yuan, up 23.68% [2][12] - The main brand, Proya, generated 8.581 billion yuan in revenue, representing 79.69% of total revenue, with a growth of 19.55% [2][12] - The skincare category contributed 90.19 billion yuan, accounting for 83.78% of total revenue, with a growth of 19.31% [2][12] Future Projections - The company expects revenues of 12.469 billion yuan, 14.257 billion yuan, and 16.093 billion yuan for 2025, 2026, and 2027 respectively [3][4] - Projected net profits for the same years are 1.840 billion yuan, 2.150 billion yuan, and 2.441 billion yuan [3][4] - The report anticipates a decrease in the price-to-earnings ratio from 20 times in 2025 to 15 times in 2027, indicating improving valuation [3][4]

据了解，此前太二酸菜鱼作为九毛九的核心业务，长期贡献超过七成的营收，然而，最近一年其业务数 据并不好看。 根据最新的2024年业绩公告，九毛九2024年实现营收60.74亿元，同比增加1.47%；归母净利润5580.70 万元，同比下降87.69%；年度溢利4480万元，同比减少90.7%，大幅缩水。 对于业绩下滑，九毛九归因于三方面原因：餐饮市场竞争加剧叠加外部环境变化导致同店收入下滑；闭 店及经营不善引发的一次性闭店与资产减值损失约1.35亿元；政府补贴及税收优惠减少，叠加汇兑损失 增加。 据了解，作为九毛九营收占比超七成的"现金牛"，太二酸菜鱼增长已显疲态。财报显示，2024年太二酸 菜鱼实现收入44.1亿元，同比下滑1.4%；翻台率从4.1次/天降至3.5次/天，顾客人均消费从75元降至71 元，同时太二酸菜鱼同店销售额也同比下降18.8%。 对此，福建华策品牌定位咨询创始人詹军豪在接受《证券日报》记者采访时表示，面对业绩下滑，太二 酸菜鱼的变化是应对市场变化的必然选择，但调整效果如何还有待观察。太二酸菜鱼增加菜品可能吸引 到更多消费者，尤其是对酸菜鱼兴趣不大的顾客，但也可能让原有的品牌定位被稀释，影 ...

答：2024 年公司销量较大的产品有六味地黄丸、逍遥丸、 安宫牛黄丸、归脾丸、二陈丸、参茸固本还少丸等产品，前十大 产品占营业收入的近 50%。公司未来将持续推进大单品开发战 略，巩固并提升六味地黄丸系列等传统浓缩丸产品的市场占有 率，加大对参茸固本还少丸、复方黄芪健脾口服液等独家品种以 及二陈丸、安宫牛黄丸、八珍丸、安神补心丸、阿胶等市场需求 较大产品的销售。 3.2025 年一季度毛利率及净利率提升的原因？ 答：公司一是优化营销渠道管控，拓宽销售渠道，深化合作， 实现线上线下销售结合，进一步提高市场占有率；二是针对不同 渠道对产品进行梳理细化，不同渠道采用不同的销售政策及价格 管控措施；三是今年中药材价格有所回落，生产成本降低。综上 所述，2025 年一季度毛利率和净利率有所提升。 证券代码：002644 证券简称：佛慈制药 4.2024 年和 25Q1 销售费用率下降的原因？ 兰州佛慈制药股份有限公司 投资者关系活动记录表 编号：20250428 | □特定对象调研 | 分析师会议 | | --- | --- | | 投资者关系 | □媒体采访 □业绩说明会 | | 活动类别 | □新闻发布会 □路演 ...

Investment Rating - The investment rating for the company is "Add" [4] Core Views - The company has maintained impressive growth in net profit, achieving a revenue of 10.778 billion yuan in 2024, a year-on-year increase of 21.04%, and a net profit of 1.552 billion yuan, up 30.00% year-on-year [1][12] - The main brand, Proya, has launched new product lines targeting oily skin and whitening, while multiple sub-brands have also seen growth [2] - Online sales channels have continued to grow rapidly, with online revenue reaching 10.234 billion yuan in 2024, a year-on-year increase of 23.68%, accounting for 95.06% of total revenue [10] Summary by Sections Financial Performance - In 2024, the company reported a net profit of 1.552 billion yuan, with a net profit margin of 14.71%, an increase of 0.89 percentage points year-on-year [11] - The company’s gross margin improved to 71.39%, up 1.46 percentage points year-on-year, driven by lower freight rates and higher average transaction values [11] - The company expects net profits of 1.853 billion yuan, 2.171 billion yuan, and 2.516 billion yuan for 2025, 2026, and 2027 respectively, with corresponding PE ratios of 18, 15, and 13 times [12] Product Development - Proya has focused on upgrading its core products, introducing unique ingredients such as "XVII type recombinant collagen" in its new product lines [2] - The new product lines include the "净源系列" for oily skin and the "光学系列" for whitening, contributing to the brand's revenue growth [2] Market Position - Proya's main brand generated 8.581 billion yuan in revenue in 2024, accounting for 79.69% of total revenue, with strong performance on platforms like Tmall [2] - The sub-brand 彩棠 achieved revenue of 1.191 billion yuan, while OR and 悦芙媞 also reported significant growth in their respective markets [2] Sales Channels - Online sales accounted for a significant portion of revenue, with direct and distribution channels contributing 8.122 billion yuan and 2.112 billion yuan respectively [10] - The company is optimizing its offline store structure, although offline revenue decreased by 13.63% to 532 million yuan in 2024 [10]

Core Insights - Proya has become the first Chinese beauty brand to achieve over 10 billion RMB in revenue, with 2024 revenue reaching 10.778 billion RMB, a year-on-year increase of 21.04% [1][4][5] - The net profit for 2024 was 1.552 billion RMB, reflecting a 30% year-on-year growth [1][4] - Proya's main brand revenue reached 8.581 billion RMB, marking a 19.55% increase, making it the first domestic beauty brand to surpass 8.5 billion RMB [5][7] Revenue Breakdown - Proya's revenue from the "Cai Tang" brand reached 1.191 billion RMB in 2024, up 19.04%, contributing to the company's second growth curve [7] - Online sales accounted for 10.234 billion RMB, a 23.68% increase, representing 95.06% of total revenue, while offline sales decreased to 532 million RMB, down 13.63% [5][8] Financial Performance - The gross margin for Proya's main business increased to 71.41%, up 1.41 percentage points year-on-year, with online gross margin at 72.01% and offline at 59.89% [8] - Sales expense ratio rose to 47.88%, an increase of 3.27 percentage points, attributed to higher promotional expenses [8] R&D and Management Changes - R&D expenses for 2024 were 210 million RMB, a 21.21% increase, accounting for 1.95% of total revenue [9] - The company underwent a management change with Hou Yamen taking over as General Manager from co-founder Fang Yuyou, who remains as a consultant [10] Shareholder Returns - Proya plans to distribute a cash dividend of 11.90 RMB per 10 shares, totaling approximately 469 million RMB, which represents 40.07% of the net profit for the year [11][12]

Brand Performance - The brand "Winona Baby" achieved revenue of over 200 million RMB, a year-on-year growth of 34% in 2024 [2] - The brand "Aikeman" generated approximately 60 million RMB in revenue, with a year-on-year increase of over 65% [2] - "Jirui" reported revenue of 470 million RMB in 2024, while "Bomei" generated over 50 million RMB, contributing significantly to the company's growth [2] Profitability and Financial Metrics - The company's gross profit margin improved from 73.74% in 2024 to 77.47% in Q1 2025 [3] - Cumulative dividends from 2021 to 2024 amounted to 1.098 billion RMB, representing 34.60% of the net profit attributable to shareholders during this period [3] - The 2024 dividend was approximately 250 million RMB, accounting for over 50% of the net profit attributable to shareholders [3] Inventory and Supply Chain Management - Inventory turnover rate increased from 1.78 times/year in 2023 to 1.87 times/year in 2024, a growth of 5.43% [3] - Inventory decreased from over 900 million RMB at the end of 2023 to 600 million RMB by the end of 2024, and further down to 560 million RMB by the end of Q1 2025 [3] Marketing and Sales Strategies - The brand "Aikeman" ranked among the top 6 new beauty brands on Tmall during the "Double 11" shopping festival in 2024 [4] - "Jirui" saw a 56% year-on-year increase in search index on Douyin for its core product, while its sunscreen category experienced a 97% increase [4] - "Bomei" achieved a 1181% year-on-year increase in search index for its flagship product on Douyin [4] Offline and Online Channel Development - The OTC distribution channel covered over 129,000 pharmacy stores nationwide by the end of 2024 [5] - The company opened 179 new brand direct stores in key urban areas, enhancing brand visibility and service capabilities [5] - The self-built OMO online sales platform saw large orders (over 1000 RMB) account for approximately 62.82% of total orders, with an average transaction value exceeding 1500 RMB [5]

整理 ｜ 彭倩 #Big News# 增长压力之下，雀巢中国换帅 雀巢中国的首位本土 CEO 卸任。 近日，雀巢宣布现任雀巢大中华区董事长兼 CEO 张西强辞任，由现任菲律宾市场负责人马凯思 （Kais Marzouki）接替。这是雀巢集团自去年10月宣布不再将中国市场设立为独立大区后（今年1 月1日起生效），推出的一项人事调整举措。 由于中国市场曾表现颇佳，雀巢曾在2022年为其单独设立大中华区，张西强同年成为雀巢中国首位 本土CEO。中国是雀巢的第二大市场，一直被寄予厚望，张西强在上任时也曾为雀巢中国制定较为乐 观的增长计划：雀巢中国区要在2025年实现600亿小目标，在2030年实现1000亿大目标。 翻看过去3年的财报，雀巢中国区的体量分别为401.6亿元、436亿元和408.69亿元，遇到增长瓶 颈，与张西强曾制定的2025年达到600亿的目标也相差较大。 如今，全球消费市场正处于周期性波动，雀巢在内的一系列外资企业都需要更好的让产品适应当地市 场消费者需求和习惯的变化。 雀巢曾公开表示对中国市场的反思，前 CEO 施耐德曾表示，过去10年，雀巢在中国多项投资没有成 功，如对花生牛奶品牌银鹭的收购， ...

编号：2025-008 证券代码：002127 证券简称：南极电商 南极电商股份有限公司投资者关系活动记录表 | 投资者关系活 | □ 特定对象调研 √ 分析师会议 | | --- | --- | | 动类别 | □ 媒体采访 □ 业绩说明会 | | | 路演活动 □ 新闻发布会 □ | | | □ 现场参观 | | | □ 其他 | | 参与单位名称 | 中信建投证券、招商证券、华泰证券、长江证券、申万宏源证 | | 及人员姓名 | 券、广发证券、天风证券、浙商证券、国海证券、东吴证券、 | | | 德邦证券、国盛证券、华西证券、西南证券、博时基金、嘉实 | | | 基金、广发基金、金鹰基金、申万菱信、华泰资管、浦银安盛、 | | | 中银基金、博道基金、信泰人寿、Dymon Asia Capital (HK) | | | Limited、广汇缘资管、同泰基金、银华基金、建信理财、百 | | | 年保险资管、上海水璞、同犇投资、彝川资本、湖南源乘、兴 | | | 银基金、新华基金、民生加银、长安基金、厦门坤易、万家基 | | | 金、浙商资管、清和泉资本、鹏扬基金、上海川流、中泰资管、 | | | 进门财经 ...